Category: Oncology
Hematology/Oncology Diversity and Inclusion Initiatives
黑料网 Lineberger Comprehensive Cancer Center聽Equity Council Sam Cykert, MD, and Marjory Charlot, MD. Four members of the Department of Medicine are working to bring diversity, equity and inclusion principles into critical areas of 黑料网 Lineberger. 鈥淭his is a group of 14 faculty, graduate students, and staff–and we鈥檙e in the process of identifying patients and community members–com … Read more
Breast Cancer Awareness Month–Caring for Patients, Advancing Research
Behind every photo is a story with the power to uplift and inspire. One year has made all the difference for Frances Lucas from Fayetteville, who was diagnosed with breast cancer in May 2020. And, it was something Dr. Yara Abdou said that set the tone for her journey. 鈥淪he said, ‘I鈥檓 not only going to be your doctor, I want to be your friend,’ 鈥� recalls Frances from her first app … Read more
Muss Receives Three Research Grant Awards
Hyman Muss, MD Hyman Muss, MD, the Mary Jones Hudson Distinguished Professor of Geriatric Oncology in the Division of Oncology, recently received three research awards. From the Breast Cancer Research Foundation (BCRF), Muss received $190,000 in funding for “p16INK4a Expression, Chemotherapy Toxicity, and Aging in Women with Breast Cancer.”聽There is significant variability in che … Read more
Department of Medicine Grants & Funding: September 1 鈥� September 30, 2021
Division of Gastroenterology and Hepatology Andrea Azcarate-Peril, PhD, received an NC TraCS聽pilot grant award. Division of Geriatric Medicine Joshua Niznik, PharmD, PhD, received an NC TraCS聽pilot grant award. 黑料网鈥檚 Center for Aging and Health received a two-year Health Resources and Services Administration (HRSA), Department of Health and Human Services grant聽(with University o … Read more
Chemotherapy Plus Immunotherapy Before Surgery is Beneficial For Invasive Bladder Cancer Outcomes
Tracy Rose, MD, MPH A new study is the first to report the beneficial use of chemotherapy plus immunotherapy before surgical removal of the bladder in muscle-invasive bladder cancer (MIBC). Researchers at the 黑料网 Lineberger Comprehensive Cancer Center led the study, reporting that the regimen reduced the invasiveness of the cancer in 56 percent of patients in a phase II clinical … Read more
Roundtable Discussion: Weiss Discusses Treatment of RET-Fusion Mutations in NSCLC
Jared Weiss, MD Jared Weiss, MD, associate professor in the division of oncology, led a recent discussion about a 59.year-old patient with RET-fusion-positive non鈥搒mall cell lung cancer (NSCLC) during a Targeted Oncology Case-Based Roundtable event. Read a transcript of the discussion.
To Boost Covid-19 Vaccine Uptake, Stein Describes Early Strategy To Identify Those Who May Have Missed System-Wide Communication
Jacob Stein, MD As public health leaders double down on efforts to get shots to the 30% of eligible people in the U.S. that remain unvaccinated, STAT News featured 黑料网 Health’s unique strategy to reach those who might have fallen through the cracks. During the early days of vaccine rollout 鈥渨e realized that the vast majority of this communication was being done either by email or … Read more
-
New Therapies For Elderly, Frail Patients With Head and Neck Cancer
Jared Weiss, MD Jared Weiss, MD, associate professor of medicine in the division of oncology, commented on one of two treatment regimens that have shown promise for treating elderly or frail patients with head and neck squamous cell carcinoma, according to researchers. 鈥淭hese results are consistent with those observed in the dose-escalation part of the study and suggest durable e … Read more
Experimental Drug That Boosts Immunotherapy, Shows Promise in Bladder Cancer Study
William Kim, MD A new study in mice found that adding the experimental drug entinostat to an immunotherapy-like treatment substantially boosted cancer remission. This approach shows such promise that it鈥檚 already being tested in an ongoing clinical trial in people with advanced bladder cancer. This finding, led by William Kim, MD, professor of medicine in the division of oncology … Read more
ONCLive Features Carey Discussing Updated Results of PALOMA-3 Trial
Lisa Carey, MD, FASCO Lisa A. Carey, MD, FASCO, the Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research in the Department of Medicine’s Division of Oncology recently discussed the updated results of the phase 3 PALOMA-3 trial (NCT01942135) in hormone receptor (HR)鈥損ositive, HER2-positive breast cancer. Hear Carey explain the results on ONCLive.
Zeidner Discusses Pevonedistat Which Shows Promising Partner Potential for HMAs in Higher-Risk MDS
Joshua Zeidner, MD Joshua F. Zeidner, MD, discussed the role hypomethylating agents (HMAs) have played in the treatment of higher-risk myelodysplastic syndrome (MDS) in a recent聽OncLive聽report. He shared data that shows promising emerging agents like pevonedistat that can be combined with HMAs to improve outcomes for certain patient subsets. 鈥淲e really have not had any new agents … Read more
Advanced Bladder Cancers Respond to Immunotherapy Regardless of Gene Mutation Status
Tracey Rose, MD, MPH, and William Kim, MD A new study demonstrates patients with advanced bladder cancers whose tumors have a mutated FGFR3 gene respond to immunotherapy treatment in a manner that is similar to patients without that mutation, a discovery that runs counter to previous assumptions. Led by scientists in the Department of Medicine and members of the Lineberger Compre … Read more